214 related articles for article (PubMed ID: 30244558)
1. Botulinum neurotoxin for the treatment of movement disorders.
Kopanidis P; Das C
Aust J Gen Pract; 2018 Sep; 47(9):598-601. PubMed ID: 30244558
[TBL] [Abstract][Full Text] [Related]
2. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin for the treatment of movement disorders.
Thenganatt MA; Fahn S
Curr Neurol Neurosci Rep; 2012 Aug; 12(4):399-409. PubMed ID: 22661378
[TBL] [Abstract][Full Text] [Related]
4. Long-term adherence and response to botulinum toxin in different indications.
Lee JI; Jansen A; Samadzadeh S; Kahlen U; Moll M; Ringelstein M; Soncin G; Bigalke H; Aktas O; Moldovan AS; Waskoenig J; Jander S; Gliem M; Schnitzler A; Hartung HP; Hefter H; Albrecht P
Ann Clin Transl Neurol; 2021 Jan; 8(1):15-28. PubMed ID: 33259153
[TBL] [Abstract][Full Text] [Related]
5. Use of botulinum toxin in neuro-ophthalmology.
O'Day J
Curr Opin Ophthalmol; 2001 Dec; 12(6):419-22. PubMed ID: 11734681
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Ababneh OH; Cetinkaya A; Kulwin DR
Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore.
Tan AK
Singapore Med J; 1998 Sep; 39(9):403-5. PubMed ID: 9885719
[TBL] [Abstract][Full Text] [Related]
8. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
9. [Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment].
Costa PG; Cardoso IP; Saraiva FP; Raiza AC; Tanaka LK; Matayoshi S
Arq Bras Oftalmol; 2006; 69(3):319-22. PubMed ID: 16936952
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of botulinum toxin in neurological indications.
Ward AB; Molenaers G; Colosimo C; Berardelli A
Eur J Neurol; 2006 Dec; 13 Suppl 4():20-6. PubMed ID: 17112346
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin in movement disorders.
Papapetropoulos S; Singer C
Semin Neurol; 2007 Apr; 27(2):183-94. PubMed ID: 17390263
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
[TBL] [Abstract][Full Text] [Related]
13. Comparison of techniques of botulinum toxin injections for blepharospasm and hemifacial spasm.
Sacramento DRC; Lima A; Maia DP; Cunningham M; Maciel RH; Camargos ST; Cardoso F
Mov Disord; 2019 Sep; 34(9):1401-1403. PubMed ID: 31251420
[No Abstract] [Full Text] [Related]
14. [Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin].
Yabiku MM; Sartori Jde F; Sarraff EP; Osaki TH; Hossaka SK; Pereira CI; Freitas Wd; Osaki MH; Cariello AJ
Arq Bras Oftalmol; 2011; 74(6):414-6. PubMed ID: 22331113
[TBL] [Abstract][Full Text] [Related]
15. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
[TBL] [Abstract][Full Text] [Related]
16. [Botulinum toxin therapy for focal dystonia].
Hahn K; Niklai E; Garzuly F; Szupera Z
Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
[TBL] [Abstract][Full Text] [Related]
17. Experience with long-term treatment with albumin-supplemented botulinum toxin type A.
Mohammadi B; Kollewe K; Wegener M; Bigalke H; Dengler R
J Neural Transm (Vienna); 2009 Apr; 116(4):437-41. PubMed ID: 19319477
[TBL] [Abstract][Full Text] [Related]
18. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
Rollnik JD; Matzke M; Wohlfarth K; Dengler R; Bigalke H
Eur Neurol; 2000; 43(1):9-12. PubMed ID: 10601802
[TBL] [Abstract][Full Text] [Related]
19. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm.
Jost WH; Kohl A
J Neurol; 2001 Apr; 248 Suppl 1():21-4. PubMed ID: 11357234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
